BCL-2 | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Regulatory

25 March 2024

Ascentage’s Venclexta challenge looks wildly optimistic

A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.

Conferences Trial results

14 December 2023

ASH 2023 – Sympatico gives Imbruvica a second chance

Regulatory

13 October 2023

Two BCL-2 inhibitors feature in phase 3 starts

Subscribe to BCL-2